Alkermes Announces Results From Phase 2 Study Of ALKS 33 In Alcohol Dependence

Alkermes Announces Results From Phase 2 Study Of ALKS 33 In Alcohol Dependence
Alkermes, Inc. (NASDAQ: ALKS) announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes’ proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 …
Read more on Medical News Today

Weight-loss drug cleared by FDA panel
Advisors recommend the approval of Contrave despite concerns about its safety — particularly its impact on blood pressure — and effectiveness. An advisory panel to the Food and Drug Administration set aside lingering concerns about the safety and marginal effectiveness of the latest weight-loss drug to come before it, voting 13 to 7 on Tuesday to recommend the approval of Contrave, a combination …
Read more on Los Angeles Times

Biotech Report: Diet-drug makers rally on FDA vote
Shares of Orexigen, Arena and Vivus rise on news that an FDA advisory panel is backing the approval of Orexigen’s diet pill Contrave.
Read more on Market Watch